Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0890 • ACR Convergence 2021
Depression Is Associated with Frailty in Systemic Lupus Erythematosus Patients: Multicenter Retrospective Analysis Using Systemic Lupus Erythematosus International Collaborating Clinics-Frailty Index
Kichul Shin¹, In Ah Choi², Eunyoung Lee³, SE RIM CHOI⁴, Jina Yeo⁵, Yun Jong Lee⁶, Su-Jin Yoo⁷, Bong-Jin Hahm⁴, Jee Eun Park⁴, Ju Ho Lee⁸, Yeong-Wook Song⁴ and Ju Yeon Kim⁴, ¹Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea, ²Chungbuk National University Hospital, Cheongju, Republic of Korea, ³Uijeongbu Eulji Medical Center, Seoul, South Korea, ⁴Seoul National University Hospital, Seoul, Republic of Korea, ⁵Gil Medical Center, Seoul, South Korea, ⁶Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea, ⁷Chungnam National University Hospital, Daejeon, Republic of Korea, ⁸Seoul National University Bundang Hospital, Yongin Si, Republic of Korea
Background/Purpose: Systemic Lupus Erythematosus International Collaborating Clinics-Frailty Index (SLICC-FI) is a novel health measure in systemic lupus erythematosus (SLE) and was reported to have impact…
Abstract Number: 1029 • ACR Convergence 2021
Evaluation of the EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a Population-Based Registry
Allison Guttmann¹, Brendan Denvir¹, Jill Buyon², Martin Aringer³, H. Michael Belmont², Sara Sahl⁴, Jane Salmon⁵, Anca Askanase⁶, Joan Bathon⁷, Laura Geraldino⁸, Yousaf Ali⁹, Ellen Ginzler¹⁰, Chaim Putterman¹¹, Caroline Gordon¹², Charles Helmick¹³, Hilary Parton¹⁴ and Peter Izmirly¹, ¹New York University School of Medicine, New York, NY, ²NYU School of Medicine, New York, NY, ³Rheumatology, Medicine III, University Medical Center & Faculty of Medicine, TU Dresden, Dresden, Germany, ⁴UCLA-Harbor, Los Angeles, CA, ⁵Hospital for Special Surgery, New York, NY, ⁶Columbia University Medical Center, New York, NY, ⁷Columbia University, New York, NY, ⁸New York Presbyterian Hospital - Columbia Campus, New York, NY, ⁹Icahn School of Medicine at Mount Sinai, New York, NY, ¹⁰SUNY Downstate Health Sciences University, Brooklyn, NY, ¹¹Albert Einstein College of Medicine, Bronx, NY, ¹²Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ¹³Centers for Disease Control and Prevention, Atlanta, GA, ¹⁴New York City Department of Health and Mental Hygiene, Long Island City, NY
Background/Purpose: The Manhattan Lupus Surveillance Program (MLSP) is a multi-racial/ethnic population-based registry with the primary goal to determine the prevalence and incidence of Systemic Lupus…
Abstract Number: 1163 • ACR Convergence 2021
Patients’ Insights About Hydroxychloroquine, and Patient-Recommended Strategies to Target Nonadherence
Shivani Garg¹, Betty Chewning¹, Noah Kaitz¹, Shelby Gomez¹ and Christie Bartels², ¹UW Madison, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Hydroxychloroquine (HCQ) is the cornerstone of SLE therapy as it improves damage-free survival in all SLE patients. Yet, in new users, as few as…
Abstract Number: 1270 • ACR Convergence 2021
Disease Severity and Healthcare Costs Associated with Chronic Kidney Disease in Patients with Systemic Lupus Erythematosus
Shirley Huang¹, Amy Guisinger², Carlyne Averell¹ and Christopher Bell¹, ¹GlaxoSmithKline, Research Triangle Park, NC, ²US Value, Evidence and Outcomes, GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose: Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE), occurring in approximately 40% of SLE patients (pts) and often resulting in…
Abstract Number: 1286 • ACR Convergence 2021
Twenty-Year Trends in Systemic Lupus Erythematosus All–Cause Mortality in Mexico: A Nationwide Health Registry
Claudia Mendoza-Pinto¹, Ivet Etchegaray-Morales², Mario García-Carrasco², Pamela Munguía-Realpozo² and Socorro Méndez-Martínez³, ¹Instituto Mexicano del Seguro Social, San Andres Cholula, Mexico, ²Benemérita Universidad Autónoma de Puebla, Puebla, Mexico, ³Instituto Mexicano del Seguro Social, Puebla, Mexico
Background/Purpose: Marked regional variation in systemic lupus erythematosus (SLE) mortality may be due to different spectra of local environmental factors. There have been no large…
Abstract Number: 1303 • ACR Convergence 2021
Associations Between Early Changes in Circulating B Cell Subsets and Severe Flare in Systemic Lupus Erythematosus – Results from Three Phase III Trials of Belimumab
Ioannis Parodis¹, Alvaro Gomez², Julius Lindblom², Alexander Borg², Sharzad Emamikia² and Mariele gatto³, ¹Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden and Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden, ²Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ³Department of Rheumatology, University of Padua, Padua, Italy
Background/Purpose: Belimumab is the only approved targeted treatment for systemic lupus erythematosus (SLE). Identification of early predictors of response or non-response to therapy is imperative…
Abstract Number: 1464 • ACR Convergence 2021
Ambulatory Fetal Heart Rate Monitoring (FHRM) to Surveil Pregnancies at Risk for Congenital Heart Block
Mala Masson¹, Colin Phoon¹, Elena Sinkovskaya², Lisa Howley³, Ruben Acherman⁴, Majd Makhoul⁵, Nelangi Pinto⁶, Miao Chang¹, Robert Clancy⁷, Bailey Drewes⁸, Bettina Cuneo⁹ and Jill Buyon⁷, ¹NYU Langone Health, New York, NY, ²East Virginia Medical School, Norfolk, ³Children's Hospitals and Clinics of Minnesota, Minneapolis, MN, ⁴Sunrise Children's Hospital, Las Vegas, NV, ⁵UK Kentucky Children's Hospital, Lexington, KY, ⁶University of Utah, Salt Lake City, UT, ⁷NYU Grossman School of Medicine, New York, NY, ⁸CU Anschutz Medical Campus, Aurora, ⁹Children's Hospital Colorado, Aurora, CO
Background/Purpose: Congenital Heart Block (CHB) complicates 2% of anti-Ro/SSA antibody positive pregnancies and carries substantial perinatal morbidity and mortality. Almost all survivors require lifelong pacing.…
Abstract Number: 1497 • ACR Convergence 2021
Kidney Disease in Lupus Patients Is Linked to Monocytes’ Aberrant Spliceosome and Altered Expression of IFN-Response Related Genes
Chary Lopez-Pedrera¹, Alejandra Patiño-Trives², Alejandro Ibañez-Costa³, Maria Luque-Tevar², Iván Arias de la Rosa⁴, Desiree Ruiz⁵, Pedro Seguí-Azpilicueta⁵, Mario Espinosa⁵, Rosa Ortega⁵, Nuria Barbarroja⁴, Justo P Cataño³, Raul Luque³, Maria Angeles Aguirre¹ and Carlos Pérez-Sánchez⁶, ¹IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ²Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, ³IMIBIC, Department of Cell Biology, Physiology and Immunology, University of Cordoba, Córdoba, Spain, ⁴University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ⁵IMIBIC, Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ⁶IMIBIC, Córdoba, Spain
Background/Purpose: The present study aimed at: 1- Identifying altered SLE monocytes transcriptomic signatures linked to the immune response and its association with clinical features. 2-…
Abstract Number: 1622 • ACR Convergence 2021
Mind the Gap: The Experience of Adolescents in a Rheumatology Transition Clinic
Claire Fine¹, Karen Beattie¹, Tania Cellucci², Liane Heale¹, Mark Matsos¹, Stephanie Garner¹ and Michelle Batthish¹, ¹McMaster University, Hamilton, ON, Canada, ²McMaster Children's Hospital, Hamilton, ON, Canada
Background/Purpose: The transition from pediatric to adult healthcare is a critical time for the wellbeing of patients with chronic illness including rheumatologic disease. Low patient…
Abstract Number: 1735 • ACR Convergence 2021
Glucocorticoid Discontinuation in Patients with Systemic Lupus Erythematosus with Prior Severe Organ Manifestation
Takehiro Nakai¹, Futoshi Iwata¹, Genki Kidoguchi¹, Sho Fukui², Hiroki Ozawa¹, Satoshi Kawaai³, Yukihiko Ikeda¹, Ayako Koido⁴, Masei Suda⁵, Atsushi Nomura⁶, Hiromichi Tamaki¹, Kenichi YAMAGUCHI¹ and Masato Okada¹, ¹St. Luke's International Hospital, Tokyo, Japan, ²Immuno-Rheumatology Center, St. Luke’s International Hospital, and Center for clinical epidemiology, St. Luke’s International University, Tokyo, Japan, ³Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, Chuo-ku, Tokyo, Japan, ⁴St. Luke's International Hospital, Akashi-cho, Chuo-ku, Tokyo, Japan, ⁵Suwa Central Hospital, Nagano, Japan, ⁶St. Luke's International Hospital, Nagareyama, Japan
Background/Purpose: Most long-term damage in systemic lupus erythematosus (SLE) has been attributed to continuous glucocorticoid use; however, glucocorticoid discontinuation is occasionally associated with disease flare-ups.…
Abstract Number: 1756 • ACR Convergence 2021
Class V Systemic Lupus Erythematosus Nephritis Patients Are Undertreated and Face Similar Adverse Renal Outcomes as Class III/IV Patients
April Barnado and Alex Camai, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Few studies have investigated treatment patterns and renal outcomes in class V systemic lupus erythematosus (SLE) nephritis patients compared to class III/IV patients. Prior…
Abstract Number: 1841 • ACR Convergence 2021
Presence of Autoantibodies to Dense-Fine-Speckled 70 (DFS70) Do Not Necessarily Rule out Connective Tissue Diseases
Louisa-Marie Mockenhaupt¹, Ramona Dolscheid-Pommerich¹, Charlotte Behning¹, Birgit Stoffel-Wagner², Peter Brossart¹ and Valentin Schäfer¹, ¹University Hospital Bonn, Bonn, Germany, ²University Hospital Bonn, Bonn
Background/Purpose: Antinuclear antibodies (ANA) are serological markers for the presence of connective tissue diseases [1]. In some patients, a pattern can be detected in ANA…
Abstract Number: 0134 • ACR Convergence 2021
Systemic Lupus Erythematosus Is a Risk Factor for Mortality in Older Patients with Early-Stage Breast Cancer
Sebastian Bruera¹, Xiudong Lei², Xerxes Pundole², Hui Zhao², Sharon Giordano², Surabhi Vinod¹ and Maria Suarez-Almazor², ¹Baylor College of Medicine, Houston, TX, ²University of Texas MD Anderson Cancer Center, Houston, TX
Background/Purpose: Women with systemic lupus erythematosus (SLE) who develop breast cancer (BC), may receive different therapies (e.g. radiation) than women with BC who do not…
Abstract Number: 0333 • ACR Convergence 2021
Validation of the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) Classification Criteria for Systemic Lupus Erythematosus (SLE) in Hong Kong Chinese
Chi Chiu Mok¹, Yuen Kwan Chung², Carolyn Lee³, Ling Yin Ho⁴ and Chi Hung To², ¹Tuen Mun Hospital, Hong Kong, China, ²Pok Oi Hospital, Hong Kong, Hong Kong, ³Hospital Authority, Hong Kong, Hong Kong, ⁴Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose: To validate the 2019 EULAR/ACR classification criteria for SLE in Hong Kong Chinese patients and compare its performance with the 2012 Systemic Lupus International…
Abstract Number: 0351 • ACR Convergence 2021
Gene Signature Fingerprints Divide SLE Patients in Subgroups with Similar Biological Disease Profiles: A Multicenter Longitudinal Study
Javad Wahadat¹, Dieneke Schonenberg-Meinema², Cornelia van Helden-Meeuwsen¹, Sander van Tilburg¹, Noortje Groot³, Ellen Schatorjé⁴, Esther Hoppenreijs⁴, Petra Hissink Muller⁵, Danielle Brinkman⁶, Denis Dvorak⁷, Marleen Verkaaik³, Katerina Bouchalova⁸, Merlijn van den Berg², Sylvia Kamphuis⁹ and Marjan Versnel¹, ¹Erasmus University Medical Center, Rotterdam, Netherlands, ²Emma Children's Hospital, Amsterdam University Medical Center, Amsterdam, Netherlands, ³Sophia Children's Hospital, Erasmus University Medical Center, Rotterdam, Netherlands, ⁴Amalia Children's Hospital, Nijmegen, Netherlands, ⁵Willem Alexander Children’s Hospital, Leiden University Medical Center, Leiden, Netherlands, ⁶Willem Alexander Children’s Hospital, Leiden University Medical Center, Leiderdorp, Netherlands, ⁷Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital, Olomouc, Czech Republic, ⁸Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic, ⁹Sophia Children’s Hospital, Erasmus University Medical Center, Rotterdam, Netherlands
Background/Purpose: Clinical phenotyping and predicting treatment responses in Systemic Lupus Erythematosus (SLE) patients is challenging. Extensive blood transcriptional profiling has identified various gene modules that…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].